Drug
Folfirinox clinical trials
- studies test it
- 53
- open now
- 10
- in phase 3
- 5
- first study started
- 2004
Keep track of what changes. Save the folfirinox studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
52 studies that test it; most in 2020 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 12
- Phase 2
- 37
- Phase 3
- 5
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 50
Massachusetts General Hospital (3) · Institut du Cancer de Montpellier - Val d'Aurelle (3) · Sun Yat-sen University (3) · University of Louisville (2) · Indiana University (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Seoul National University Hospital (2) · University of Cincinnati (1)
Often tested with
Tested in the same studies.
Gemcitabine (11) · Albumin-Bound Paclitaxel (6) · Paclitaxel (6) · Pembrolizumab (3) · FOLFIRI-Ziv-aflibercept Regimen (3) · FOLFIRI Regimen (3) · GNP Regimen (2) · Folfox protocol (2)
Studies
Open first, then newest update. How each study uses folfirinox is read from its arms, and is right about nine times in ten.
Testing it · 53
- Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.Not yet recruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07808567Written as FOLFIRINOX
- Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic CancerRecruitingPhase 2Baylor College of MedicineNCT05132504Written as Folfirinox
- Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 2Shanghai General Hospital, ChinaNCT07733050Written as FOLFIRINOX/NALIRIFOX
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingEarly Phase 1Northwell HealthNCT07193862Written as Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingPhase 1University of California, IrvineNCT05733689Written as FOLFIRINOX
- Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaRecruitingPhase 1University of LouisvilleNCT03484299Written as FOLFIRINOX
- mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer PatientsRecruitingPhase 2Sun Yat-sen UniversityNCT04084496Written as Folfirinox
- NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)RecruitingPhase 3Seoul National University HospitalNCT05529940Written as Folfirinox
- Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic CancerRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT05462496Written as FOLFIRINOX
- Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric CancerRecruitingPhase 2Instituto do Cancer do Estado de São PauloNCT03825861Written as FOLFIRINOX
- FOLFIRINOX + RT for Pancreatic CancerCompletedPhase 2Massachusetts General HospitalNCT01591733Written as FOLFIRINOX
- Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic AdenocarcinomaActive, not recruitingPhase 2University of CincinnatiNCT04594772Written as Folfirinox
- Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood TestActive, not recruitingPhase 3UNICANCERNCT07340567Written as Folfirinox
- Radiation w/FOLFIRINOX-Losartan for Pancreatic CancerCompletedPhase 2Massachusetts General HospitalNCT01821729Written as FOLFIRINOX
- Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal CancerCompletedPhase 1/2Institut du Cancer de Montpellier - Val d'AurelleNCT03828799Written as Folfirinox + regorafenib
- Pancreatic Adenocarcinoma Signature Stratification for TreatmentCompletedPhase 2University Health Network, TorontoNCT04469556Written as Folfirinox
- Intensified Chemotherapy in CRC After Resection of Liver MetastasesCompletedPhase 2/3Institut du Cancer de Montpellier - Val d'AurelleNCT00208260Written as FOLFIRINOX
- Redefining FOLFIORINOX in Older Pancreatic Cancer PatientsActive, not recruitingPhase 2Fox Chase Cancer CenterNCT05360732Written as FOLFIRINOX
- Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal AdenocarcinomaCompletedPhase 1Georgetown UniversityNCT04292743Written as FOLFIRINOX
- First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus FirgemCompletedPhase 2Federation Francophone de Cancerologie DigestiveNCT02352337Written as FOLFIRINOX
See all 53 studies that test folfirinox →
Given in every arm · 11 — folfirinox is usual care beside what is tested
- Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)RecruitingPhase 1/2Phanes TherapeuticsNCT05482893Written as FOLFIRINOX
- A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05458219Written as FOLFIRINOX/mFOLFIRINOX
- Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)RecruitingPhase 1/2Amsterdam UMC, location VUmcNCT06384560Written as Folfirinox
- LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm StudyRecruitingPhase 1/2Zhejiang Provincial People's HospitalNCT07312422Written as FOLFIRINOX regimen
- Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic CancerRecruitingPhase 1/2Changhai HospitalNCT04324307Written as FOLFIRINOX
- FOLFIRINOX + NIS793 in Pancreatic CancerTerminatedPhase 1Colin D. Weekes, M.D., PhDNCT05417386Written as FOLFIRINOX
- Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic CancerActive, not recruitingPhase 2Massachusetts General HospitalNCT03563248Written as FOLFIRINOX
- CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without PanitumumabActive, not recruitingPhase 1/2Anup KasiNCT05121038Written as Folfirinox
- Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the PancreasCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01595321Written as FOLFIRINOX
- Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic CancerTerminatedPhase 3NewLink Genetics CorporationNCT01836432Written as FOLFIRINOX
- Pancreatic Locally Advanced Irresectable Cancer AblationStatus unknownNot applicableAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT03690323Written as FOLFIRINOX
As the comparator · 2 — what is tested is compared with folfirinox
- Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingPhase 1/2UNC Lineberger Comprehensive Cancer CenterNCT06483555Written as Folfirinox
- Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the PancreasCompletedPhase 3Cornerstone PharmaceuticalsNCT03504423Written as Folfirinox
Codes
What other systems call folfirinox · ClinicalTrials.gg INT000958
- MeSH (NLM) C000627770folfirinoxOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627770 | folfirinox | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.